The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
The current study was initiated to explore the mechanisms underlying the previously demonstrated association between the proliferative activity of leukaemic blasts and the response to cytosine arabinoside (AraC)-based therapy in de novo acute myeloid leukaemia (AML). The activity of key enzymes of AraC metabolism-deoxycytidine kinase (DCK), cytidine deaminase (DCD) and polymerase alpha (PolyA) were determined in blast cells from 33 patients. In addition, formation and retention of intracellular levels of AraC triphosphate (AraCTP) and DNA incorporation of AraC were measured, as was the proliferative activity of leukaemic blasts by [3H]-TdR incorporation before and after stimulation with granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte CSF (G-CSF) for 48 h. AraC incorporation into the DNA (median 0.60 pmol/105 cells) was significantly related to the proliferative activity of AML blasts (r = 0.74, P < 0.001). Similarly, priming with GM-CSF or G-CSF increased both the proliferative activity of AML blasts by a median of 1.84- and 1.64-fold, respectively, and the incorporation of AraC into the DNA (1.29- and 1.40-fold respectively). In contrast, no relationship was found between the endogenous proliferative activity (EPA) and enzyme activities regulating AraC activation (DCK; median 4.70 pmol/min/mg protein), inactivation (DCD; median 2.92 pmol/min/mg protein) or inhibitory effects (PolyA; median 1.50 pmol/min/mg protein), nor the formation or retention of AraCTP (median 306.1 ng/107 cell and 1.6 h respectively). When samples were grouped according to EPA (more than or less than the median), slowly proliferating specimens had a higher response to cytokine priming for proliferative activity and incorporation of AraC into DNA. Clinical data of 15 patients were available. Although all eight patients with a high endogenous proliferative activity reached complete remission, only four out of seven patients with a low proliferative activity responded, whereas the other three patients were non-responders (P = 0.077).
Braess
J
J
Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians University, Munich, Germany. jan.braess@med3.med.uni-muenchen.de
Voss
S
S
Jahns-Streubel
G
G
Schoch
C
C
Haferlach
T
T
Kern
W
W
Keye
S
S
Schleyer
E
E
Hiddemann
W
W
D000208:Acute Disease; D000328:Adult; D000368:Aged; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D003564:Cytidine Deaminase / Q000032:analysis; D004247:DNA / Q000378:metabolism; D003842:Deoxycytidine Kinase / Q000032:analysis; D005260:Female; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D016014:Linear Models; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D013997:Time Factors
D007166:Immunosuppressive Agents; D003561:Cytarabine; D004247:DNA; D003842:Deoxycytidine Kinase; D003564:Cytidine Deaminase